US Patent Issued to Resverlogix on July 7 for "Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor" (Canadian Inventors)

ALEXANDRIA, Va., July 7 -- United States Patent no. 12,673,059, issued on July 7, was assigned to Resverlogix Corp. (Calgary, Canada).

"Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor" was invented by Kenneth Eugene Lebioda (Calgary, Canada), Christopher Ross Armstrong Halliday (Calgary, Canada) and Aziz Naeem Khan (Calgary, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described herein are methods for treating and/or preventing a kidney disease or an associated disorder as measured by an increase in estimated glomerular filtration rate (eGFR) by administering to a subject in need thereof, a combination of a s...